• Skip to primary navigation
  • Skip to main content
AMRA MedicalAMRA Medical

AMRA Medical

Precision for Decision

  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Set Up
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Media
  • About Us
    • About AMRA
    • Our Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us

AMRA Medical’s Study on MRI-Based Muscle Composition in Diabetes Selected for EASD 2020

September 22, 2020
  • Facebook
  • Twitter
  • LinkedIn
  • Mail

AMRA Medical assessed prevalence of sarcopenia, adverse muscle composition, and low functional performance within Type 2 Diabetes and will present at EASD virtual meeting.

Linköping, Sweden, September 22, 2020: AMRA, in partnership with Linköping University, evaluated the prevalence of sarcopenia, low functional performance, and adverse muscle composition (AMC) – measured by magnetic resonance imaging (MRI) – in Type II Diabetes (T2D) and will present the results at the European Association for the Study of Diabetes annual meeting 2020, 21 – 25 September.

The research was based on 9,724 UK Biobank participants and utilized functional measures (e.g. hand grip strength, stair climbing, number of falls), dual energy X-ray absorptiometry, and questionnaire data to determine the prevalence of sarcopenia and low functional performance. AMRA utilized AMRA® Researcher to quantify fat-free muscle volume and muscle fat infiltration from MRI. Each participant was then assigned a personalized muscle volume z-score, calculated using virtual control groups 1 to detect AMC. Prevalence of sarcopenia, low functional performance, and AMC in participants with T2D were compared to those without T2D.

AMRA researchers found that although the prevalence of sarcopenia was similar between those with and without T2D, low functional performance was higher in T2D – reflecting a limitation with the current definition of sarcopenia. Interestingly, AMC was significantly more common in T2D (26%) compared to individuals without T2D (9.5%). The research data indicate that sarcopenia-related issues are much more common in those with T2D compared to those without T2D, but can go undetected by current sarcopenia tools, whereas MRI-based muscle composition provides a more accurate description of a patient’s muscle status.

AMRA will present “Adverse Muscle Composition in T2D – Results from the large UK Biobank Imaging Study”, presentation number 972 at EASD online September 24th at 1:15 pm – 2:15 pm CET during Poster Session: PS 96 Tradition? No! Non-traditional complications of diabetes.

Learn more about AMRA’s research, capabilities, and opportunities for collaboration by attending AMRA’s digital poster presentation at EASD 2020 and visiting www.amramedical.com

 

About AMRA Medical

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA’s aim is to support transformative care and vital decision-making from clinical research to health and wellness.

 

ContactRosemary Shull
SVP Global BD & Marketing
rosemary.shull@amramedical.com

 

1Linge et al, J Gerontol A Biol Sci Med Sci 2020. doi: 10.1093/gerona/glz229

All posts
  • Facebook
  • Twitter
  • LinkedIn
  • Mail
AMRA Medical
Follow us

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

  • Data Privacy Policy
  • Cookie Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support

Newsletter

© 2025 AMRA Medical AB
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}